GIM
AZN icon

Glenmede Investment Management’s AstraZeneca AZN Stock Holding History

Glenmede Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$9.44M Sell
61,525
-1,013
-2% -$153K 0.05% 363
2025
Q2 		$8.74M Buy
+62,538
New +$8.76M 0.04% 372

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Glenmede Investment Management's AZN Position: Q3 2025 in Review

Glenmede Investment Management reduced its AstraZeneca (AZN) stake by 1.6% in Q3 2025, selling an estimated $153K and leaving 61,525 shares worth $9.44M. The position accounts for 0.05% of the portfolio, ranked #363.

Glenmede Investment Management first reported a position in AZN in Q2 2025 and has held it in 2 quarters since. 1,288 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

  • Glenmede Investment Management held 61,525 shares of AstraZeneca worth $9.44M as of Q3 2025.
  • Glenmede Investment Management sold 1,013 AstraZeneca shares in Q3 2025, an estimated $153K.
  • AstraZeneca made up 0.05% of Glenmede Investment Management's portfolio in Q3 2025, its #363 holding.
  • Glenmede Investment Management first reported a position in AstraZeneca in Q2 2025 and has held it in 2 quarters since.
  • 1,288 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.